RECURSION PHARMACEUTICALS, INC.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Recursion Pharmaceuticals (RXRX) stock rose 7.23% after reporting AI-driven drug discovery progress and cost-cutting measures. The company reported Q2 2026 revenue of $7.7M and a net loss of $131M, with $545M in cash. Analysts have mixed views, with a mean price target of $7.22. RXRX is focusing on AI-driven drug development and has partnerships with companies like Genentech.
Recursion Pharmaceuticals (RXRX) stock rose 7.61% after positive AI-driven drug discovery results. The company reported Q2 2026 revenue of $7.7M, a net loss of $131M, and $545M in cash. It reduced its FY26 expense guidance to $375M, extending its cash runway into early 2028. Analysts have mixed views, with a consensus target of $7.22.
Recursion Pharmaceuticals (RXRX) is under scrutiny for its clinical pipeline and AI platform. Key milestones include Phase 2 data for REC-4881 and early results for REC-1245, with partnerships potentially unlocking milestone payments. The company's cash burn extends runway into early 2028. Investors debate the AI platform's ability to deliver consistent clinical wins. Q2 revenue missed expectations, and insiders have sold shares. Institutional investors have mixed positions, with some adding and
Over the past 7 days, alphai's AI scored 2 news stories mentioning RXRX (RECURSION PHARMACEUTICALS, INC.). Coverage has skewed bullish: 1 bullish, 1 neutral, and 0 bearish.
Recent RXRX coverage spans earnings, market movers and financial news.
In the last 30 days, RXRX insiders filed 1 SEC Form 4 transaction — no purchases and 1 sale ($98K). The most active reporter was Borgeson Blake with 1 filing. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
Positive cash runway and partnership news may support short‑term upside, but heavy losses and execution risk keep downside potential.
Strong cash runway and partner validation may support short‑term upside, but continued large losses keep downside risk high.
Negative pressure on stock due to insider sell‑offs and declining revenue.
Near-term sentiment appears pressured by the earnings read-through (lower sales/revenue), while valuation narratives diverge (fair value $1.97 vs price $3.16).
Negative earnings surprise is directly tied to a down move, increasing near-term downside risk until the next update.
alphai scores every news story that mentions RXRX with an AI model for sentiment and relevance, and aggregates insider trades from RECURSION PHARMACEUTICALS, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Recursion Pharmaceuticals (RXRX) stock rose 7.23% after reporting AI-driven drug discovery progress and cost-cutting measures. The company reported Q2 2026 revenue of $7.7M and a net loss of $131M, with $545M in cash. Analysts have mixed views, with a mean price target of $7.22. RXRX is focusing on AI-driven drug development and has partnerships with companies like Genentech.
3 min readRecursion Pharmaceuticals (RXRX) stock rose 7.61% after positive AI-driven drug discovery results. The company reported Q2 2026 revenue of $7.7M, a net loss of $131M, and $545M in cash. It reduced its FY26 expense guidance to $375M, extending its cash runway into early 2028. Analysts have mixed views, with a consensus target of $7.22.
3 min readRecursion Pharmaceuticals (RXRX) is under scrutiny for its clinical pipeline and AI platform. Key milestones include Phase 2 data for REC-4881 and early results for REC-1245, with partnerships potentially unlocking milestone payments. The company's cash burn extends runway into early 2028. Investors debate the AI platform's ability to deliver consistent clinical wins. Q2 revenue missed expectations, and insiders have sold shares. Institutional investors have mixed positions, with some adding and
2 min readSimply Wall St reports Recursion Pharmaceuticals (RXRX) shares fell after its 2Q and first-half 2026 results showed sharply lower sales and revenue, though net loss narrowed year over year. The article cites RXRX down 4.53% (1 day) and 1.86% (7 days). It also notes a “fair value” of $1.97 versus $3.16 and a DCF cash-flow value of $9.80.
6 min readBenzinga reports Jim Cramer’s comments alongside recent earnings updates. Vistra missed Q2 revenue and EPS estimates but grew adjusted EBITDA and reaffirmed full-year outlook. Recursion Pharmaceuticals reported worse-than-expected Q2 results. NextEra Energy had mixed Q2 results and reaffirmed guidance. Huntington Ingalls beat Q2 results and raised FY26 sales guidance. Fastly’s Q2 EPS beat estimates. Shares moved modestly.
3 min readRecursion (RXRX) discussed Q2 2026 progress on its internal pipeline and partnerships. It cited FDA engagement and upcoming Phase II updates for REC-4881, IND clearance for REC-7735, and continued Phase I dose escalation for REC-1245. With Roche-Genentech, it announced a first neuroscience target entering a joint early discovery program, and said it has achieved over $260M in upfront and milestones with potential for $300M+ more per program.
7 min readAnthropic is reportedly targeting an IPO in September or early October 2026, according to the Wall Street Journal. In investor meetings, it said it plans to expand healthcare and biology AI use cases. The article highlights potential AI-biotech beneficiaries, citing results and guidance for Absci, Recursion, Schrodinger, Twist Bioscience, and Tempus AI, including Tempus Q2 revenue of $382.49M and raised FY guidance to $1.595 to $1.605B.
6 min readAnalysts covering Recursion Pharmaceuticals (NASDAQ:RXRX) cut 2026 revenue forecasts by 19%, lowering consensus to about $53m, down 3.9% versus the prior 12 months. Loss per share is expected to improve slightly to about $0.88 versus $0.87 previously. The article also cites an expected annual revenue decline through 2026 versus prior growth.
2 min readRecursion Pharmaceuticals (RXRX) reported Q2 GAAP results with a net loss of $131.005 million, or -$0.25 per share, compared with a $171.897 million loss, or -$0.41 per share, a year earlier. Revenue fell 42.0% to $7.670 million from $13.223 million.
1 min readRecursion Pharmaceuticals (Nasdaq: RXRX) reported second-quarter results for the period ended June 30, 2026 and provided pipeline updates. Genentech exercised an option to advance the collaboration’s first neuroscience target into an early discovery program. Recursion cut 2026 cash operating expense guidance to under $375 million. It also updated REC-4881 Phase 2 plans and said REC-7735 Phase 1/2 starts in 2H26.
6 min read
